Beta Bionics (NASDAQ:BBNX) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Beta Bionics (NASDAQ:BBNX) from a hold rating to a sell rating in a research note published on Saturday morning.

Other equities analysts also recently issued research reports about the stock. Truist Financial increased their price target on shares of Beta Bionics from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 price objective (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. The Goldman Sachs Group raised their target price on shares of Beta Bionics from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Piper Sandler restated an “overweight” rating and set a $32.00 target price (up from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Finally, Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and an average price target of $30.20.

Beta Bionics Price Performance

NASDAQ BBNX opened at $17.65 on Friday. The company has a market cap of $777.13 million and a price-to-earnings ratio of -4.04. The stock’s fifty day moving average price is $29.08 and its 200 day moving average price is $22.39. Beta Bionics has a 1 year low of $8.89 and a 1 year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $27.25 million during the quarter, compared to analysts’ expectations of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.

Insider Activity

In related news, Director Maria Palasis sold 1,406 shares of the firm’s stock in a transaction on Friday, October 31st. The shares were sold at an average price of $26.91, for a total transaction of $37,835.46. Following the sale, the director owned 9,841 shares in the company, valued at approximately $264,821.31. This trade represents a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Adam Lezack sold 1,406 shares of the company’s stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $26.87, for a total transaction of $37,779.22. Following the completion of the transaction, the director owned 9,841 shares of the company’s stock, valued at approximately $264,427.67. This trade represents a 12.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 35,302 shares of company stock valued at $1,036,449.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently bought and sold shares of the business. GPS Wealth Strategies Group LLC raised its stake in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after buying an additional 450 shares during the period. Strs Ohio purchased a new stake in Beta Bionics in the 1st quarter worth $29,000. EverSource Wealth Advisors LLC raised its position in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares during the period. CWM LLC purchased a new position in Beta Bionics during the second quarter valued at $58,000. Finally, Legal & General Group Plc lifted its holdings in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares in the last quarter.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Stifel Nicolaus reaffirmed its Buy rating on Beta Bionics, supporting the view that some sell‑side analysts still see upside. Stifel Nicolaus Reaffirms Their Buy Rating on Beta Bionics, Inc. (BBNX)
• Positive Sentiment: Lake Street also maintained its Buy rating, another signal that some analysts continue to back the company’s longer‑term prospects. Lake Street Keeps Their Buy Rating on Beta Bionics, Inc. (BBNX)
• Neutral Sentiment: Comparative coverage: a head‑to‑head survey article compares Beta Bionics to Tenon Medical — useful for competitive context but not an immediate catalyst. Head-To-Head Survey: Beta Bionics (NASDAQ:BBNX) vs. Tenon Medical (NASDAQ:TNON)
• Negative Sentiment: Multiple law firms announced securities‑fraud investigations into Beta Bionics (DJS Law Group, Frank R. Cruz, Faruqi & Faruqi). These notices typically follow an adverse disclosure or results that could prompt litigation risk and increased investor caution. Beta Bionics, Inc. Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights – BBNX
• Negative Sentiment: Additional firm-led probes were announced (Frank R. Cruz and Faruqi & Faruqi), each urging investors who lost money to inquire about claims — these amplify legal and reputational risk and often lead to selling pressure. INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
• Negative Sentiment: The Law Offices of Frank R. Cruz separately announced an investigation tied to Beta Bionics’ January disclosures, reinforcing legal risk headlines. Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
• Negative Sentiment: Short interest jumped materially in December to about 7.30M shares (≈16.6% of shares short), a large rise that can amplify downside pressure and increase volatility if holders cover. This higher short interest is a direct bearish signal. (Data entry)
• Neutral Sentiment: There is a reporting anomaly on short interest as of Jan. 12 showing zero shares — treat that as likely erroneous and rely on the Dec. 31 figure until corrected. (Data entry)
• Negative Sentiment: Bank of America cut Beta Bionics to Neutral, removing a prior bullish stance and reducing buy‑side support from a major institutional analyst. Beta Bionics (NASDAQ:BBNX) Cut to Neutral at Bank of America

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.